{
    "nct_id": "NCT06005493",
    "official_title": "A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Age ≥ 18 at the time of signing the informed consent\n* Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas\n* Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)\n* Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening\n* Predicted life expectancy of ≥ 12 weeks\n* Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol\n* Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol\n* Must have received at least one prior line of systemic therapy in the advanced/metastatic setting\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for those defined by the protocol\n* Participant experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy\n* Previous history of hemophagocytic lymphohistiocytosis (HLH) / macrophage activation syndrome (MAS)\n* Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment\n* central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent\n* Infectious disease including active human immunodeficiency virus (HIV), active hepatitis B/C, uncontrolled infection with EBV, uncontrolled active systemic fungal, bacterial or other infection\n* Cardiac conditions as defined by the protocol\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention\n* Participant requires chronic immunosuppressive therapy\n* Participants on anticoagulation therapy",
    "miscellaneous_criteria": "Key"
}